Cancer gene therapy developer aims for $60M IPO; Nanowafers as an alternative to eye drops?;

> Cancer gene therapy developer MultiVir aims to raise $60 million via Nasdaq IPO that is supposed to commence during the week of May 4. More

> Contract manufacturer Recipharm agreed to produce LIDDS' phase II Liproca Depot, a reformulated candidate to treat prostate cancer via local administration. More

> Researchers at Baylor College Medicine are working on the use of drug delivering nanowafers as an alternative to eye drops. More

> New York City's Anterios--the developer of a lotion containing the active ingredient of Botox (marketed by recently acquired Allergan) that can be applied on the skin via a 10-minute massage--plans to raise $51 million via Nasdaq IPO. Earlier this month, it filed with the SEC to raise $58 million. More

Suggested Articles

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.

Astex's oral reformulation of a common chemo combo looks to replace lengthy infusions with a once-daily tablet that patients can take at home.